Document is current
Any future updates will be listed below
-
Authors
Fridén, Michael
Rosqvist, Fredrik
Kullberg, Joel
Berglund, Lars https://orcid.org/0000-0002-7437-9047
Vessby, Johan
Martinell, Mats
Carlsson, Per-Ola
Hulthe, Johannes
Johansson, Lars https://orcid.org/0000-0001-5954-3497
Ahmad, Nouman
Johansson, Hans-Erik
Rorsman, Fredrik
Sundström, Johan https://orcid.org/0000-0003-2247-8454
Lind, Lars
Landberg, Rikard https://orcid.org/0000-0002-6399-7608
Orho-Melander, Marju https://orcid.org/0000-0002-3578-2503
Ahlström, Håkan
Risérus, Ulf https://orcid.org/0000-0002-8620-4586
-
Funding
Funding for this research was provided by:
Hjärt-Lungfonden (Dnr: 20180709)
Svenska Forskningsrådet Formas (Dnr: FR-2019/0007)
Swedish Diabetes Foundation and Excellence of Diabetes Research in Sweden
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 20 October 2025
First Online: 13 December 2025
Competing interests
: J.V. reports advisory board for Novo Nordisk, and lecture fees from Gore Medical and Norgine. J.S. reports direct or indirect stock ownership in companies (Anagram kommunikation AB, Sence Research AB, Symptoms Europe AB, MinForskning AB), providing services to companies and authorities in the health sector, including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma, WeMind. J.K. reports being co-founder, stock owner and part time employee at Antaros Medical AB. No other competing interests are reported.
